Remove Biosimilars Remove Diabetes Remove Webinar
article thumbnail

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

PharmaVoice

In general, the megablockbuster trend is skewing toward drugs that reach a wider range of patients, such as checkpoint inhibitors like Keytruda and GLP-1 weight loss and diabetes medications. Combined, Lilly’s Mounjaro, for diabetes, and Zepbound, for obesity, raked in $16.5 billion last year.

Diabetes 147
article thumbnail

Grail plans FDA filing for cancer blood test after new trial

pharmaphorum

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Caris swells its planned IPO, seeking $5.7bn valuation

pharmaphorum

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

ADA: Lilly makes its case for oral GLP-1 orforglipron

pharmaphorum

Skip to main content Monday 23 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

Update: Rumour confirmed as Lilly buys Verve Therapeutics

pharmaphorum

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

article thumbnail

Most pharmas not ready for AI in customer engagement

pharmaphorum

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)